Author Archives: admin


Stem Cell Clinic > Articles by: admin

UCLA Researchers Identify Unique Protein Key to the Development of Blood Stem Cells

By Uncategorized

Contact Information

Available for logged-in reporters only

Newswise Led by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research member Dr. Hanna Mikkola, UCLA scientists have discovered a unique protein that is integral to the self-renewal of hematopoietic stem cells (HSCs) during human development.

This discovery lays the groundwork for researchers to generate HSCs in the lab (in vitro) that better mirror those that develop in their natural environment (in vivo). This could lead to improved therapies for blood-related diseases and cancers by enabling the creation of patient-specific blood stem cells for transplantation.

The findings are reported online November 13, 2014, ahead of print in the journal Cell Stem Cell.

The research community has long sought to harness the promise of pluripotent stem cells (PSCs) to overcome a significant roadblock in making cell-based therapies blood and immune diseases more broadly available, which has been hampered by the inability to generate and expand human HSCs in culture. HSCs are the blood forming cells that serve as the critical link between PSCs and fully differentiated cells of the blood system. The ability of HSCs to self-renew (replicate themselves) and differentiate to all blood cell types, is determined in part by the environment that the stem cell came from, called the niche.

In the five-year study, Mikkola and Drs. Sacha Prashad and Vincenzo Calvanese, members of Mikkolas lab and lead authors of the study, investigated a unique HSC surface protein called GPI-80. They found that it was produced by a specific subpopulation of human fetal hematopoietic cells that were the only group that could self-renew and differentiate into various blood cell types. They also found that this subpopulation of hematopoietic cells was the sole population able to permanently integrate into and thrive within the blood system of a recipient mouse.

Mikkola and colleagues further discovered that GPI-80 identifies HSCs during multiple phases of human HSC development and migration. These include the early first trimester of fetal development when newly generated HSCs can be found in the placenta, and the second trimester when HSCs are actively replicating in the fetal liver and the fetal bone marrow.

We found that whatever HSC niche we investigated, we could use GPI-80 as the best determinant to find the stem cell as it was being generated or colonized different hematopoietic tissues, said Mikkola, associate professor of molecular, cell and development biology at UCLA and also a member of the Jonsson Comprehensive Cancer Center. Moreover, loss of GPI-80 caused the stem cells to differentiate. This essentially tells us that GPI-80 must be present to make HSCs. We now have a very unique marker for investigating how human hematopoietic cells develop, migrate and function.

Mikkolas team is actively exploring different stages of human HSC development and PSC differentiation based on the GPI-80 marker, and comparing how blood stem cells are being generated in vitro and in vivo. This paves the way for scientists to redirect PSCs into patient-specific HSCs for transplantation into the patient without the need to find a suitable donor.

Read the rest here:
UCLA Researchers Identify Unique Protein Key to the Development of Blood Stem Cells

Researchers Discover Breakthrough Stem Cell Treatment For Parkinson's Disease

By Stem Cell Treatment

By C. Rajan, contributing writer

Researchers at Lund University in Sweden have made a major breakthrough in Parkinson's disease treatment by developing stem cell-derived brain cells that can replace the cells lost due to the disease, thus paving the way for the first stem cell transplant treatment for Parkinsons patients.

Parkinson's disease, which affects about 10 million people worldwide, is a degenerative nervous system condition which causes tremors, muscle weakness, stiffness, and loss in mobility. Parkinson's is caused by loss of dopamine-producing neurons in the brain. Dopamine is an essential neurotransmitter that is required for regulating movement and emotions.

In this study, for the first time ever, the researchers were able to convert human embryonic stem cells into dopamine producing neurons, which behaved like native dopamine cells lost in the disease.

The study was led by Malin Parmar, associate professor in Lund's Department of Medicine, and conducted at both Lund University and at MIRCen in Paris as part of the EU networks NeuroStemCell and NeuroStemcellRepair.

According to Medical News Today, the researchers produced rat models of Parkinson's disease by destroying the dopamine cells in one part of the rat's brain, and then they transplanted the new dopamine producing stem cell neurons. These next generation dopamine neurons were found to survive long term, restore the lost dopamine, and form long distance connections to the correct parts of the brain when transplanted into rats. Most excitingly, these transplanted stem cells reversed the damage from the disease.

As the new dopamine neurons have the same properties and functions of native cells lost in Parkinson's disease and can be produced in unlimited quantities from stem cell lines, this treatment shows promise in moving into clinical applications as stem cell transplants for Parkinsons.

"This study shows that we can now produce fully functioning dopamine neurons from stem cells. These cells have the same ability as the brains normal dopamine cells to not only reach but also to connect to their target area over longer distances. This has been our goal for some time, and the next step is to produce the same cells under the necessary regulations for human use. Our hope is that they are ready for clinical studies in about three years", says Malin Parmar.

Human embryonic stem cells (ESC) are powerful treatment options due to their ability to change into any cell type in the body. However, it is difficult to get them to change into the desired cell types, and research efforts are also hampered due to the ethical concerns associated with embryonic stem cells.

The study is published in the journal,Cell Stem Cell, titled Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinsons Disease.

See original here:
Researchers Discover Breakthrough Stem Cell Treatment For Parkinson's Disease

Ilfords Fathima Hilmy finds possible stem cell match in Brazil

By Stem Cell Doctors

12:44 11 November 2014

Harry Kemble

Fathima Hilmy, of High Road, Ilford.

Archant

A 25-year-old teaching assistant may have had her international appeal for a stem cell donor answered.

Email this article to a friend

To send a link to this page you must be logged in.

Sri Lankan Fathima Hilmy, of High Road, Ilford - known as Fathima Nusla by her community - has been told by doctors she has an 80 per cent chance of a successful match after a potential donor was found in Brazil.

The unnamed donor will now be medically tested to see if they can undergo the intensive and challenging procedure.

Fathima, 25, has been in and out of hospital after being originally diagnosed with acute myeloid leukaemia in 2012.

Go here to read the rest:
Ilfords Fathima Hilmy finds possible stem cell match in Brazil

Toughest for Tamil Nadu patients to get donor stem cells

By Stem Cell Medicine

CHENNAI: It is harder for natives of Tamil Nadu to find a matching donor for a stem cell transplant compared to other states in the country. The suspected villain: Their genes.

A study published recently in British medical journal 'The Lancet' found that the likelihood of finding a matching stem cell donor for patients with blood-related problems in Tamil Nadu is 44.2% provided the registry had 10 lakh donors. The situation is the opposite in Haryana, with people in that state having the best chances (81.2%) of finding a donor.

Experts say consanguineous marriages are to blame. Consanguineous marriages increase the chances of patients finding a match within their small community but limit the possibility of finding one from a general donor pool.

"Unlike in other countries, stem cell variation in India is complex and dependent on ethnic variation," said Dr Dolly Daniel, professor of the department of transfusion medicine at Christian Medical College, Vellore, who was party of the study team. "Our aim was to find the size and genetic composition of each region and its impact on the proportion of patients who will be able to ?nd a suitable match."

She said Tamil Nadu could be at the tail-end of the list of states they surveyed because of inbreeding and a limited number of donors.

Stem cells are used to regenerate and repair diseased or damaged tissues. Adult stem cells are drawn from bone marrow, blood and the umbilical cord and are used to treat blood-related ailments like leukemia, thalassemia and as well as immunodeficiency.

The possibility of finding a matching stem cell donor within the family is around 30%.

"Finding a matching stem cell donor for the remaining 70% is a complex process. Most seek a graft from registries of unrelated adult donors or banked umbilical cord blood units," said Dr P Srinivasan, co-founder and chairman of Jeevan Stem Cell Bank.

Although the India stem cell industry is estimated to touch $540 million (Rs 3,250 crore) by 2015, the study noted that in terms of the number of donors, India has lagged in meeting demand. The study surveyed 10 adult donor and umbilical cord bank registries and clinical transplant centres in India and studied stem cells of 26 239 individuals.

The possibility of finding a perfect match within India is an average of 14.4% for a registry size of 25,000 and touches 60.6% for a size of 10 lakh. Registries in the country currently have around 1 lakh donors. The study said only when Indian registries have more than 2 lakh donors would patients have a good chance of finding the right match.

The rest is here:
Toughest for Tamil Nadu patients to get donor stem cells

STEM CELL FINDING WELL-NOTED IN LA JOLLA STEM CELL FINDING SHOWS PROMISE

By Uncategorized

By Bradley J. Fikes U-T5:05 a.m.Nov. 12, 2014

A rat model of Parkinsons disease has been successfully treated with neurons derived from human embryonic stem cells, according to a new study led by Swedish scientists.

Its a promising sign for scientists at The Scripps Research Institute and Scripps Health who hope to perform similar therapy on Parkinsons patients using artificial embryonic stem cells.

In rats and people, neurons that make the neurotransmitter dopamine are essential for normal movement. Parkinsons destroys those cells, leading to the movement difficulties that characterize the disease.

Researchers transplanted dopamine-producing cells grown from human embryonic stem cells into the brains of rats whose own dopamine-making neurons had been destroyed. Within five months, the transplanted cells boosted dopamine production to normal levels, restoring normal movement in the rats.

The study was published Thursday in the journal Cell Stem Cell. The senior author was Malin Parmar of Lund University in Sweden.

The results support the Scripps approach of using artificial embryonic stem cells called induced pluripotent stem cells, or IPS cells said Jeanne Loring, head of the Center for Regenerative Medicine at Scripps Research. Loring and the Scripps Health network are part of a group called Summit 4 Stem Cell thats raising funds to treat eight Parkinsons patients with their own IPS cells.

Particularly significant is the studys comparison of the effects of dopamine-making neurons derived from fetal cells to those of embryonic stem cells, Loring said by email.

In the 1980s and 1990s, there were several clinical trials that showed that grafts of fetal brain containing the precursors of dopamine neurons could reverse the effects of Parkinsons disease in some patients, Loring said. We and the others developing stem cell therapies based our plans on the results of those studies, but no one had ever directly compared fetal tissue and human pluripotent stem cell-derived dopamine neurons in an animal model of (Parkinsons).

Induced pluripotent stem cells appear to have much the same capacity as human embryonic stem cells to generate different tissues and organs.

See original here:
STEM CELL FINDING WELL-NOTED IN LA JOLLA STEM CELL FINDING SHOWS PROMISE

STEM CELL FINDING WELL-NOTED IN LA JOLLA

By Uncategorized

By Bradley J. Fikes U-T5:08 a.m.Nov. 12, 2014

A rat model of Parkinsons disease has been successfully treated with neurons derived from human embryonic stem cells, according to a new study led by Swedish scientists.

Its a promising sign for scientists at The Scripps Research Institute and Scripps Health who hope to perform similar therapy on Parkinsons patients using artificial embryonic stem cells.

In rats and people, neurons that make the neurotransmitter dopamine are essential for normal movement. Parkinsons destroys those cells, leading to the movement difficulties that characterize the disease.

Researchers transplanted dopamine-producing cells grown from human embryonic stem cells into the brains of rats whose own dopamine-making neurons had been destroyed. Within five months, the transplanted cells boosted dopamine production to normal levels, restoring normal movement in the rats.

The study was published Thursday in the journal Cell Stem Cell. The senior author was Malin Parmar of Lund University in Sweden.

The results support the Scripps approach of using artificial embryonic stem cells called induced pluripotent stem cells, or IPS cells said Jeanne Loring, head of the Center for Regenerative Medicine at Scripps Research.

Loring and the Scripps Health network are part of a group called Summit 4 Stem Cell thats raising funds to treat eight Parkinsons patients with their own IPS cells.

Particularly significant is the studys comparison of the effects of dopamine-making neurons derived from fetal cells to those of embryonic stem cells, Loring said by email.

In the 1980s and 1990s, there were several clinical trials that showed that grafts of fetal brain containing the precursors of dopamine neurons could reverse the effects of Parkinsons disease in some patients, Loring said. We and the others developing stem cell therapies based our plans on the results of those studies, but no one had ever directly compared fetal tissue and human pluripotent stem cell-derived dopamine neurons in an animal model of (Parkinsons).

Read more here:
STEM CELL FINDING WELL-NOTED IN LA JOLLA

Study Identifying Cell of Origin for Large, Disfiguring Nerve Tumors Lays Groundwork for Development of New Therapies

By Stem Cell Medical Center

Contact Information

Available for logged-in reporters only

Newswise DALLAS November 11, 2014 UTSouthwestern Medical Center researchers have determined the specific type of cell that gives rise to large, disfiguring tumors called plexiform neurofibromas, a finding that could lead to new therapies for preventing growth of these tumors.

This advance provides new insight into the steps that lead to tumor development and suggests ways to develop therapies to prevent neurofibroma formation where none exist today, said Dr. Lu Le, Assistant Professor of Dermatology at UTSouthwestern and senior author of the study, published online and in Cancer Cell.

Plexiform neurofibromas, which are complex tumors that form around nerves, occur in patients with a genetic disorder called neurofibromatosis type 1 (NF1), which affects 1 in 3,500 people. About 30 percent of NF1 patients develop this type of tumor, which is typically benign.

NF1 patients with plexiform neurofibromas, however, have a 10 percent lifetime risk of the tumors developing into malignant peripheral nerve sheath tumors (MPNSTs), a deadly, incurable type of soft-tissue cancer. In addition, due to their unusual capacity for growth, plexiform neurofibromas can be life-threatening by their physical impairment of vital organs or neural function.

While there are no currently approved therapies for either MPNSTs or plexiform neurofibromas, Dr. Le said determining the cell type and location from which these tumors originate is an important step toward discovering new drugs that inhibit tumor development.

If we can isolate and grow the cells of origin for neurofibromas, then we can reconstruct the biological steps that lead these original cells to tumor stage, said Dr. Le, a member of the Harold C. Simmons Cancer Center. Once we know the critical steps in the process, then we can design inhibitors to block each step in an effort to prevent or slow tumor formation.

Using a process called genetic labeling for cell fate tracing, researchers determined that plexiform neurofibromas originate from Schwann cell precursors in embryonic nerve roots.

This study addresses a fundamental question in the neurofibromatosis field, Dr. Le said. It points to the importance of stem cells and their immediate progenitors in the initiation of tumors, consistent with the notion that these neoplasms originate in a subset of primitive precursors and that most cells in an organ do not generate tumors.

Read more from the original source:
Study Identifying Cell of Origin for Large, Disfiguring Nerve Tumors Lays Groundwork for Development of New Therapies

Global Stem Cells Group Announces Plans to Hold Four International Symposiums on Stem Cells and Regenerative Medicine …

By Uncategorized

MIAMI (PRWEB) November 11, 2014

GlobalStemCellsGroup, Inc. has announced plans to host a minimum of four international symposiums on stem cell research in 2015. The symposiums will be held in three Latin American countriesChile, Mexico and Colombiain which Global Stem Cells has established state-of-the-art stem cell clinics staffed with expert medical personnel trained in regenerative medicine, through the Regenestem Network.

The fourth symposium will be held in Miami.

The decision follows the success of the Global Stem Cells Groups first International Symposium on Stem Cells and Regenerative Medicine, held Oct. 2, 3 and 4 in Buenos Aires, Argentina. Global Stem Cells Group CEO Benito Novas says the Buenos Aires event, combined with its steady growth of new clinics throughout Latin America, has provided additional motivation to schedule more stem cell symposiums in an effort to further educate the medical community on the latest advancements in stem cell therapies.

Thanks to Global Stem Cells Groups growing network of world-class stem cell researchers, treatment practitioners and investors committed to advancing stem cell medicine, the company is rapidly moving closer to its goal of helping physicians to bring treatments into their offices for the benefit of patients.

More than 900 physicians, researchers and regenerative medicine experts from around the world attended the Buenos Aires symposium, and Novas expects that number to grow with upcoming conferences.

We will continue to bring together a variety of committed stem cell advocates from the U.S., Mexico, Greece, Hong Kong and other regions around the globe, to be joined by a team of knowledgeable speakers, each one presenting the future of regenerative medicine in their field of specialty, Novas says.

Regenerative medicine as a field is still in its infancy, according to Global Stem Cell Group President and CEO Benito Novas.

Our objective is to [open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point of care medicine to the best of out abilities, Novas says. Our mission is to bring the benefits of stem cell therapies to the physicians office safely, efficacy and compliance with the highest standards of care with safety, efficacy and complying with the highest standard of care the world has to offer.

The purpose of each symposium is to bring top stem cell scientists together to share their knowledge and expertise in regenerative medicine, and begin the process of separating myths from facts when it comes to stem cell science and technology.

Read more:
Global Stem Cells Group Announces Plans to Hold Four International Symposiums on Stem Cells and Regenerative Medicine ...

Stem cell treatment for Rafas back problem

By Stem Cell Treatment

BARCELONA, SpainRafael Nadals doctor says the 14-time Grand Slam winner will receive stem cell treatment on his ailing back.

Angel Ruiz-Cotorro told The Associated Press by phone on Monday that we are going to put cells in a joint in his spine next week in Barcelona.

The Spanish tennis star was already sidelined for the rest of the season after having his appendix removed last week.

Ruiz-Cotorro, who has worked as a doctor for Nadal for the past 14 years, said Nadals back pain is typical of tennis players and that the treatment is meant to help repair his cartilage and is similar to stem cell treatment Nadal received on his knee last year.

He said Nadal, now 28, is expected to return to training in early December.

Several NFL players and baseball players have received stem cell treatment. Nadals fellow Spaniard Pau Gasol, center of the Chicago Bulls, received stem cell treatment on his knee in 2013.

Nadal experienced severe back pain during the final of the Australian Open in January when he lost to Stanislas Wawrinka.

[Nadal] has a problem typical in tennis with a back joint, he had it at the Australian Open, and we have decided to treat it with stem cells, Ruiz-Cotorro said.

The Mallorca island native has struggled with injuries in recent years. A knee injury caused him to miss several months in 2012. AP

Complete stories on our Digital Edition newsstand for tablets, netbooks and mobile phones; 14-issue free trial. About to step out? Get breaking alerts on your mobile.phone. Text ON INQ BREAKING to 4467, for Globe, Smart and Sun subscribers in the Philippines.

See more here:
Stem cell treatment for Rafas back problem

→←